Objectives: This study aimed to determine whether a gap exists between sexually transmitted infection (STI) clinicians and industry professionals regarding perceptions of the ideal types and characteristics of STI point-of-care tests (POCTs).
A lthough the World Health Organization has identified benchmarks for an ideal sexually transmitted infection (STI) point-of-care test (POCT), many currently developed or available STI POCTs are not accurate and/or are not feasible for use in clinical settings. 1, 2 This level of unsatisfactory performance results in limited or nonuse of STI POCTs by end users. Consequently, this discourages further investment and development of STI POCTs by industry. Unsatisfactory performance is, in part, due to what seems to be a gap between clinicians' (users) and industry's view of what makes an ideal STI POCT. Therefore, we conducted a study to determine whether such a gap exists. We surveyed STI clinicians/academic experts and industry professionals regarding perceptions of the ideal types and characteristics of STI POCTs.
MATERIALS AND METHODS
The online survey based on a large-scale focus group study among STI professionals 3 was conducted in 2 groups of STI professionals. The online survey questionnaire collected information regarding demographics, including sex, country of practice, and profession; barriers to use for currently available STI POCTs; characteristics of an ideal POCT; prioritization of pathogens for POCT development; and ''building your own POCT''Vpreference of POCT for STI(s) with different levels of sensitivity (70%Y79%, 80%Y89%, and Q90%), specificity (90%, 95%, and 99%), turnaround time (5, 15, and 25 minutes), and cost (US $20, $35, and $50). To identify preferred STI POCT attributes among hypothetical prospective POCTs, we used the methodology Choice Experiment, 4 which is frequently used in economics, in the ''building your own POCT.'' We randomly created 16 choice questions, each of which contained a pair of STI POCTs with different sets of attributes described above. The participants were asked to select their preferred POCT from a pair of POCTs in each choice question.
Practicing clinicians and academic experts from 3 venues, namely, STI-related international conference attendees, an international conference for obstetrician-gynecologists, and US STD clinic clinicians, were invited to participate in the clinician survey from June to August 2009. Managers of all US STD clinics (n È 700) throughout the 10 federally funded regions were contacted, and all of their clinicians were invited to participate in the online survey. Participants from 2 conference venues, the 18th Meeting of the International Society for Sexually Transmitted Diseases Research and the 39th Annual Scientific Meeting of Infectious Disease Society for Obstetrics and Gynecology, were recruited via in-person outreach, flyers, and pamphlets among attendees. Subjects were excluded from the study if they were not practicing clinicians or International Society for Sexually Transmitted Diseases Research and Infectious Disease Society for Obstetrics and Gynecology conference attendees. The results of the clinician survey have been published elsewhere. 5 Professionals from the industry in the STI diagnostic field, including biomedical researchers and business professionals, were invited via e-mails, or in-person outreach, flyers, and pamphlets at biomedical-related conferences to participate in the industry survey from June to November 2010, which used the same format as the clinician survey. Survey respondents who were not professionals from the industry in the STI diagnostic field were excluded.
Descriptive analyses were performed followed by W 2 tests to compare the responses between the results of the clinician survey and those of the industry survey. Choice modeling, a type of conditional logistic regression modeling, was used to determine the probability of individuals making a particular choice from presented options 4 for the ''build-your-own POCT'' section (SAS version 9.2 and JMP version 8; SAS Institute, Inc, Cary, NC). Subgroup analyses of choice modeling were performed for each of the top 2 prioritized pathogens chosen for STI POCT development by the participants as well as subgroup of profession (medical doctor [MD]/clinicians and non-MD professionals for clinician survey; industry business professionals and industry biomedical professionals for industry survey). All P values were 2-sided, with P G 0.05 considered to be significant.
RESULTS
Overall, 256 subjects participated in clinician survey and 218 completed the survey. In the industry survey, 149 subjects took the online survey and 107 completed the survey. The demographic characteristics of participants who completed the survey are summarized in Table 1 . Most clinician survey participants were women, whereas most industry survey participants were men. Most participants were from the United States (clinician, 78%; industry, 86%).
Clinician survey participants (n = 218) identified ''time frame required,'' ''complexity,'' and ''interruption of work flow'' as the top 3 barriers to using currently available STI POCTs, whereas the industry survey participants (n = 107) identified ''complexity,'' ''unreliability,'' and ''difficulty in reading results'' as the top 3 barriers. Significant differences in barriers named in the 2 surveys among clinicians and industry included ''complexity'' (31.2% vs 65.4%, P G 0.05), ''time frame required'' (39.9% vs 27.1%, P G 0.05), ''laboratory driven'' (29.8% vs 19.6%, P G 0.05), ''difficulty in reading results'' (9.6% vs 34.6%, P G 0.05), and ''unreliability'' (23.4% vs 53.3%, P G 0.05; Fig. 1 ). Most (78.4%) of the clinician survey participants perceived that the cost of the test from the manufacturer was a more important economic factor for a health care provider to use an STI POCT than the amount of reimbursement received for performing the test, whereas only 44.9% of industry survey participants agreed (P G 0.05).
Participants from both surveys ranked Chlamydia trachomatis as the top-priority organism chosen for a new POCT (clinician, 62%; industry, 39%; P G 0.05) followed by a test that would diagnose early seroconversion for human immunodeficiency virus (clinician, 14%; industry, 32%; P G 0.05). Ideal attributes for a new STI POCT were perceived differently by the groups. Sensitivity was always the most important attribute to be considered for a new STI POCT by both participant groups. However, participants from the clinician group chose cost as the second-priority attribute, whereas those of the industry group chose specificity as the second priority (Table 2A) . This finding mainly came from the significantly different choice between 2 groups in choosing between a test with a sensitivity of 90% to 99%, a specificity of 90%, a cost of $20, and a turnaround time of 25 minutes and a test with a sensitivity of 90% to 99%, a specificity of 99%, a cost of $35, and a turnaround time of 5 minutes. Only 5% of industry professional picked the first test, however, 21% of clinicians preferred it (P G 0.001).
For those ranking chlamydia as the top priority for STI POCT development, clinician survey participants preferred the one with highest specificity (99%), lowest cost ($20), and the fastest turnaround time (5 min), whereas industry survey participants (Table 2B) . On further subgroup analysis on the profession group, cost was ranked differently by subgroup of profession. Non-MD professionals ranked cost as the second preferred attribute after sensitivity, MD and biomedical professionals ranked cost as third, and business professionals ranked cost last. In addition, non-MD professionals preferred a cost of $20 for an ideal STI POCT, whereas the rest preferred $35. Noticeably, business professionals preferred a turnaround time of 15 minutes, whereas the rest preferred a shorter turnaround time: 5 minutes.
DISCUSSION
Significant differences in perceptions of barriers to use of currently available STI POCTs between frontline clinicians and industry professionals exist. This disagreement further extends to the perception of an ideal POCT in preferred qualities, although they agreed that test performance, cost, and turnaround time were important attributes. Huppert et al 1 have reviewed all currently available STI POCTs and found that POCTs for chlamydia and gonorrhea currently on the market for clinical use received poor scores in the authors' scoring system according to the World Health Organization's benchmark criteria for STI POCTs. The availability of unsatisfactory STI POCT products on the market may increase the probability of clinician's distrust of STI POCTs and further discourage the use of POCTs as diagnostics for patients. At the same time, industry may be discouraged by the low acceptance of STI POCTs, leading to less investment for the development of new and better STI POCTs. This cycle could hamper overall development and use of STI POCTs, thereby lessening adequate POCT and immediate treatment efforts required for curbing STI transmission in communities.
One of the major different opinions between clinicians and industry professional participants is their preferred view on cost when building an ideal STI POCT. Among 4 attributes that we investigated in this study, cost was ranked as the second preferred attribute among clinicians. However, it was ranked last among industry professionals. In addition, clinicians preferred the lowest cost in our survey, $20 per test, for general STI POCT and chlamydia POCT, whereas industry professionals settled in $35. One possible explanation is that industry professionals concern cost less because cost is not one of key elements for US Food Drug Administration diagnostics approval process. 6 On the other hand, for practicing clinicians in the public sector, cost is always going to be a top factor and the purchasing decisions are often made by nonmedical persons who are in the purchasing department. They look for ''low bid,'' and they take the clinician's desires into consideration but have other competing priorities. In the private sector, however, very often the physician makes business decisions and determines which diagnostics are to be purchased. A physician's determination of what are important test characteristics will often affect the purchase. The midlevel (non-MD) clinicians can and will influence the purchaser by making complaints when the diagnostic does not meet his or her perceived needs.
For industry, developing POCTs represents a long road ''from bench to bedside'' with enormous investment in time, money, and resources. Periodic needs assessment by the STI academic researchers to guide the development of tailored training is warranted to increase the awareness of clinicians' perceptions of ideal STI POCTs among scientists, biomedical engineers, and other industry experts. An interactive, rapid communication approach between the academic researchers and industry, such as that used by Hesse et al 7 could also decrease the differences between the perceptions of industry leaders and those of clinicians, the end users.
In summary, we demonstrated significant differences in perceptions of barriers to currently available STI POCTs and ideal POCT in preferred qualities in this study. This will let industry (the developer and the seller) understands what clinicians (the buyers) really want in STI POCTs. It is imperative for the industry to recognize the preferences because the industry needs to be able to sell the product to an end user. †Values of attributes investigated in this study included 3 levels of sensitivity (70%Y79%, 80%Y89%, and 90%Y99%), 3 levels of specificity (90%, 95%, and 99%), 3 levels of turnaround time (5, 15, and 25 minutes), and 3 levels of cost (US $20, $35, and $50).
‡Difference in preferred level of value of attributes between clinicians and industry participants.
